Mumbai, Baltimore, June 03, 2023: Global pharma major Lupin Limited (Lupin) today announced the launch of Darunavir Tablets 600 mg and 800 mg to market a generic equivalent of Prezista® Tablets of Janssen Products, LP.

Darunavir Tablets, 600 mg and 800 mg had estimated annual sales of USD 308 million in the U.S. (IQVIA MAT March 2023).

About Lupin
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on:
Twitter : https://twitter.com/LupinGlobal
LinkedIn : https://www.linkedin.com/company/lupin
Facebook : http://www.facebook.com/LupinWorld/

For further information or queries please contact –

Shweta Munjal
Vice President & Global Head – Corporate Communications
Email: shwetamunjal@lupin.com

*Safe Harbor Statement

Prezista® is a registered trademark of Janssen Sciences Ireland Unlimited Company